KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

West Pharmaceutical Services (WST) Revenue (2016 - 2026)

West Pharmaceutical Services has reported Revenue over the past 18 years, most recently at $844.9 million for Q1 2026.

  • Quarterly Revenue rose 21.05% to $844.9 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $3.2 billion through Mar 2026, up 11.23% year-over-year, with the annual reading at $3.1 billion for FY2025, 6.25% up from the prior year.
  • Revenue was $844.9 million for Q1 2026 at West Pharmaceutical Services, up from $805.0 million in the prior quarter.
  • Over five years, Revenue peaked at $844.9 million in Q1 2026 and troughed at $686.9 million in Q3 2022.
  • The 5-year median for Revenue is $746.9 million (2024), against an average of $744.1 million.
  • Biggest five-year swings in Revenue: fell 6.86% in 2024 and later rose 21.05% in 2026.
  • Tracing WST's Revenue over 5 years: stood at $708.7 million in 2022, then rose by 3.29% to $732.0 million in 2023, then rose by 2.3% to $748.8 million in 2024, then increased by 7.51% to $805.0 million in 2025, then rose by 4.96% to $844.9 million in 2026.
  • According to Business Quant data, Revenue over the past three periods came in at $844.9 million, $805.0 million, and $804.6 million for Q1 2026, Q4 2025, and Q3 2025 respectively.